BioSciCon sponsors the development of MarkPap® System, a proprietary biomarker-based technology with potentials for development of multiple medical devices for in vitro diagnostics of women’s health status. Since the beginning of clinical trials in 2001, BioSciCon has brought to commercialization phase three devices (MarkPap® Test, MarkPap® Research Kit and MarkPap® Accessories). Two new devices are currently in development, MarkPap® Digital and MarkPap® Self Kit.

The MarkPap® System is an assembly of in vitro diagnostic devices and procedures that may have practical application in cervical cancer screening for the improvement of Pap test. It is also a research tool to study cervical acid phosphatase in relation to the development of cervical pre-cancerous lesions and their transformation into cancer. In addition, MarkPap test could be used for determination of acid phosphatase in other epithelial tumors (oral, breast, lung, laryngeal, thyroid, colon, prostate) where this enzyme has been related to the tumor biology and has been considered as a target for new chemotherapies.

MarkPap® Products and Laboratory Services available for commercialization are:

• MarkPap® Test (method, assay, procedure)
• MarkPap®  Research Kit 
• MarkPap® Accessories: MarkPap® Solution

In the US, all MarkPap® products are for research only, not for diagnostic use.

For information regarding reagents, distribution and sales click on Contact Us.

For those who are interested in purchasing MarkPap products, we recommend that you get acquainted with the Introductory Letter. The Introductory Letter will be sent to customers for signing before the delivery of the merchandise.